ReviewJournal for immunotherapy of cancer2020
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Erratum issued Registry-linked trialOpen access · goldAbstract readReview
In one paragraph
Review in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05504252 (METIMMOX-2), which is not on this map. Cited by 722 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
722citing papers in PubMed, 3 pooled it
52.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05504252 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Who cites it
722 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,014 citations in OpenAlex.
- Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis.The oncologist · 2026Pooled it
- Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.Frontiers in immunology · 2026Pooled it
- Metabolic cell death in cancer: mechanisms and therapeutic potential.Apoptosis : an international journal on programmed cell death · 2025Pooled it
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906).Frontiers in immunology · 2026Trial
- Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.Oncoimmunology · 2026Review
- Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.Oncoimmunology · 2026Article
- A novel oncolytic peptide synergizing with immunotherapy.Oncoimmunology · 2026Article
- STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.Oncoimmunology · 2026Article
- An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer.Molecular cancer therapeutics · 2026Article
- Mitochondria-targeted peptide-engineered bimetallic nanozymes enable ferroptosis-sensitized cuproptosis for melanoma therapy.Materials today. Bio · 2026Article
- Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death.Journal for immunotherapy of cancer · 2026Article
- Magnetically Guided Macrophage Immunobots Coordinate Iron-Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- In Situ Bioorthogonal Synthesis of PROTACs via Dual-Responsive Cleavage for Synergistic Photo-Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ferroptosis at the Metabolic-Immune Interface in Metastatic Castration-Resistant Prostate Cancer: Mechanistic Evidence, Translational Gaps, and Combination Strategies.Annals of surgical oncology · 2026Review
- Oncolytic virus-delivered GSDME: Unlocking pyroptosis to improve dendritic cell function and amplify cytotoxic T cell response.Molecular therapy. Oncology · 2026Article
- Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nature reviews. Immunology · 2026Review
- The Relationship Between Immunogenic Cell Death and Cellular Senescence in Cancer Immunotherapy.Life (Basel, Switzerland) · 2026Review
- Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.Cell reports. Medicine · 2026Article
- "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer.Angewandte Chemie (International ed. in English) · 2026Article
662 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
54 authors at 20 institutions in 17 countries.
Lorenzo Galluzzi *Department of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA deadoc80@gmail.com.
Ilio Vitale *IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Torino, Italy.
Sarah Warren *NanoString Technologies, Seattle, Washington, USA.
Sandy AdjemianVIB Center for Inflammation Research (IRC), Ghent, Belgium.
Patrizia AgostinisCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Aitziber Buqué MartinezDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA.
Timothy A ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
George CoukosLudwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland.
Sandra DemariaDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA.
Eric DeutschDepartment of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Dobrin DraganovCalidi Biotherapeutics, San Diego, California, USA.
Richard L EdelsonDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
Silvia C FormentiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA.
Jitka FucikovaDepartment of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
Lucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Udo S GaiplUniversitätsklinikum Erlangen, Erlangen, Germany.
Sofia R GameiroLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.
Abhishek D GargCell Death Research & Therapy (CDRT) Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Encouse GoldenDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA.
Jian HaniRepertoire, Inc, Huntsville, Alabama, USA.
Kevin J HarringtonDivision of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
Akseli HemminkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
James W HodgeLaboratory of Tumor Immunology and Biology, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA.
Dewan Md Sakib HossainMerck & Co. Inc, Kenilworth, New Jersey, USA.
Tim IllidgeUniversity of Manchester, NIHR Manchester Biomedical Research Centre, Christie Hospital, Manchester, UK.
Michael KarinDepartment of Pharmacology and Pathology, University of California at San Diego (UCSD) School of Medicine, La Jolla, California, USA.
Howard L KaufmanDivision of Surgical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Oliver KeppMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Guido KroemerUniversité de Paris, Paris, France.
Juan Jose LasarteProgram of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain.
Sherene LoiDivision of Research and Clinical Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Michael T LotzeDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Gwenola ManicIIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Torino, Italy.
Taha MerghoubLudwig Collaborative and Swim Across America Laboratory, MSKCC, New York City, New York, USA.
Alan A MelcherThe Institute of Cancer Research, London, UK.
Karen L MossmanMcMaster University, Hamilton, Ontario, Canada.
Felipe ProsperHematology and Cell Therapy, Clinica Universidad de Navarra, Pamplona, Spain.
Øystein RekdalLytix Biopharma, Oslo, Norway.
Maria RescignoHumanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
Chiara RigantiDepartment of Oncology, University of Torino, Torino, Italy.
Antonella SistiguUOSD Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Mark J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Radek SpisekDepartment of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
John StaggCentre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Quebec City, Canada.
Bryan E StraussCentro de Investigação Translacional em Oncologia/LIM24, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil.
Daolin TangDepartment of Surgery, UT Southwestern Medical Center, Dallas, Texas, USA.
Kazuki TatsunoDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
Stefaan W van GoolImmun-Onkologisches Zentrum Köln, Cologne, Germany.
Peter VandenabeeleVIB Center for Inflammation Research (IRC), Ghent, Belgium.
Takahiro YamazakiDepartment of Radiation Oncology, Weill Cornell Medical College, New York City, New York, USA.
Dmitriy ZamarinDepartment of Medicine, Weill Cornell Medical College, New York City, New York, USA.
Laurence ZitvogelGustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Alessandra CesanoESSA Pharmaceuticals, South San Francisco, California, USA.
Francesco M MarincolaRefuge Biotechnologies, Menlo Park, California, USA.
Cornell University · USCharles University · CZGhent University · BEInstitute of Cancer Research · GBItalian institute for Genomic Medicine · ITMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USCentre Hospitalier de l’Université de Montréal · CACentrum für Integrierte Onkologie · DEClinica Universidad de Navarra · ESEssa Pharma (United States) · USHumanitas University · ITInserm · FRInstitut Gustave Roussy · FRiRepertoire (United States) · USIstituto Superiore di Sanità · ITKarolinska University Hospital · SEKU Leuven · BELudwig Cancer Research · CHLytix Biopharma (Norway) · NO
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI SMITH, JEFFREY W · 2009 to 2020
$19.1MVaccine and Drug Combination Therapy for Human CancersZIABC010661 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HODGE, JAMES · 2009 to 2025
$11.2MVaccine and radiation for the therapy of human cancersZIABC010975 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HODGE, JAMES · 2009 to 2025
$11.0MTargeting HMGB1-mediated Autophagy in Cancer TherapyR01CA160417 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2012 to 2023
$3.0MTargeting ACOD1 to attenuate innate immune responses to lethal infectionsR01GM127791 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI Daolin Tang · 2018 to 2026
$2.2MMechanisms of Ferroptotic Cancer Cell DeathR01CA229275 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI TANG, DAOLIN · 2019 to 2024
$1.8MCancer Research UK 21855Cancer Research UK 28724NCI NIH HHS P01 CA128814NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA160417NCI NIH HHS R01 CA229275NIGMS NIH HHS R01 GM127791
Abstract
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation.
Indexed as
ConsensusGuidelines as TopicHumansImmunogenic Cell DeathMolecular Biologyimmunologymolecular biologyoncology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05504252ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.